2 completed, 1 recruiting. 2 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow NervGen Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury NVG-291, Placebo - Chronic Spinal Cord Injury | Phase 3 | Recruiting | NervGen Pharma | 150 | 2026-09-28 | 2026-11-06 |
| NVG-291 in Spinal Cord Injury Subjects NVG-291, Placebo Injection - Spinal Cord Injuries, Chronic Spinal Cord Injury | Phase 1 / Phase 2 | Completed | NervGen Pharma | 24 | 2023-08-08 | 2026-11-20 |
| A Phase I Safety Study of NVG-291 in Healthy Adults NVG-291, Placebo - Spinal Cord Injury | Phase 1 | Completed | NervGen Pharma | 74 | 2021-05-06 | 2024-01-10 |
Spinal Cord Injuries (2) · Quadriplegia (1)
United States (2) · Australia (1) · Canada (1)
Daniel Miko, MD (1) · Randall Kaye, M.D. (1)